1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

BFI Partners with CSIR- CDRI to Advance Biomedical Innovation

30 Sep 2024
Admin
News Article

BFI Partners with CSIR- CDRI to Advance Biomedical Innovation

Overview

CSIR-Central Drug Research Institute (CDRI), a premier biomedical research institute, has announced an alliance with Blockchain For Impact (BFI) to join the BFI-BIOME Virtual Network Programme. This collaboration will nourish biomedical research and innovation to drive interventions in healthcare. The announcement was made at an event in CSIR-CDRI, Lucknow where the Memorandum of Understanding (MoU) was exchanged.

About CSIR-CDRI

CSIR-CDRI is dedicated to advancing drug discovery and development, aiming to address India’s unmet medical needs and improving public health.
This aligns very well with the mission of the BFI-BIOME Virtual Network Program, which aims to foster and support biomedical research and innovation in India to develop healthcare solutions for the Global South.
Through this partnership, BFI will fund CSIR-CDRI over a course of three years for the research and development of potential healthcare solutions.

Statement from the Leader BFI

Sandeep Nailwal, the pioneer behind BFI has expressed his excitement, “Partnering with CSIR-CDRI is certainly a step in the right direction for us. It reinforces our commitment to establish a robust healthcare ecosystem in India with home-grown, innovative solutions to the various heath afflictions faced by our masses.”
The BFI-BIOME Program is bringing together leading researchers and innovators to create a virtual network that can brainstorm and collaborate to identify and solve pressing healthcare challenges in India.

Words from the CEO: BFI

Dr Gaurav Singh, CEO of BFI, conveyed his thoughts on the newly minted partnership, “With its well-established research facilities and a history of delivering affordable drugs and molecules to the market, partnering with CSIR-CDRI is crucial to advancing our objective of developing sustainable healthcare solutions.”

Statement from the Director: CSIR-CDRI

Reflecting on the new partnership, Dr Radha Rangarajan, director, CSIR-CDRI, said, “We welcome this partnership with BFI-BIOME to advance our drug discovery portfolio. Our shared commitment to addressing India’s unmet clinical needs makes this public-private partnership particularly meaningful.”
“The projects receiving funding will build on novel and pioneering research that has been undertaken by our scientists in the fields of malaria, dengue and metabolic diseases. We look forward to being part of the BFI-BIOME network and jointly creating a new pathway for translational research.”

The Central Drug Research Institute

Central Drug Research Institute is a constituent laboratory of CSIR, under Department of Scientific & Industrial Research, Government of India, with a vision to strengthen and advance the field of drug research and development and enable affordable healthcare.

About the Company: Blockchain for Impact

Blockchain for Impact (BFI) was set up during the second wave of the Covid pandemic in India.
As the world’s most transparent healthcare fund, BFI initially worked towards strengthening the Indian healthcare system.